Inhalation Sciences signs IRS contract worth 1.39 million SEK with new US respiratory pharma client

Inhalation Sciences signs IRS contract worth 1.39 million SEK with new US respiratory pharma client

Overview

  • Post By :

  • Source: AP

  • Date: 16 Sep,2022

The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB’s leading in vitro lung simulation tool DissolvIt®.

DissolvIt® has been increasingly recognized in the inhalation industry as a leading solution for generating “IVIVC” data – that is in vitro dissolution and absorption data early on in the drug development process that closely predicts later-stage in vivo data. Such data can significantly reduce risk and costs early on in drug development.

ISAB’s contract research organization Inhalation Research Services (IRS), has signed a new contract worth 1.39 million SEK (130K Euros) with a US respiratory pharmaceutical company. The new client has chosen ISAB’s unique in vitro lung simulation tool DissolvIt® for its project.

With a growing body of publications like “In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models” (Journal of Aerosol Science 2021) there is increasing interest in DissolvIt’s advanced capabilities.

ISAB CEO Manoush Masarrat: “We are very pleased to be working with this new US client. This clearly demonstrates the client’s confidence in our world-class expertise, and the leading in vitro capabilities of DissolvIt®. We are delighted to carry out this research and look forward to this exciting collaboration.”

About Author